Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882855 | 0.93 | THRB (0.41) | MAPTPGRACLYTHRBP2RX4 | |
| SCHEMBL4880103 | 0.92 | PFKFB3 (0.40) | ALDH1A1HPGDHSD17B3HSD17B2ACLY | |
| SCHEMBL4883703 | 0.90 | PTGS1 (0.39) | ALDH1A1PGRACLYTHRBP2RX4 | |
| SCHEMBL4880023 | 0.88 | ACLY (0.45) | ALDH1A1MAPTACLY | |
| SCHEMBL4879852 | 0.86 | ALPL (0.46) | ALDH1A1LMNA | |
| SCHEMBL4881508 | 0.84 | KDM4E (0.44) | ALDH1A1HPGDSLC22A12LMNA | |
| SCHEMBL4880243 | 0.82 | GAA (0.39) | P2RX4 | |
| SCHEMBL4883423 | 0.81 | LMNA (0.42) | ALDH1A1MAPTP2RX4LMNA | |
| SCHEMBL4876500 | 0.77 | MAPT (0.49) | ALDH1A1MAPTTHRBLMNA | |
| SCHEMBL4871718 | 0.77 | MAPT (0.39) | ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799649-B1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2014-06-25 | — | — | EP | claimed |
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1799649-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006039977-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | claimed |
| EP-1799649-B1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-04-17 | — | — | US | disclosed |
| CN-101035766-A | 3-(2-hydroxyphenyl) pyrazoles and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1799649-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006039977-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1963/4885HPGD 487/4885MAPT 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.